Share Awards to Executive Directors

Eco Animal Health Group PLC

11 September 2026

 

11 September 2026

ECO Animal Health Group plc

(“ECO” or the “Company”)

Share Awards to Executive Directors

ECO Animal Health Group plc (AIM: EAH), a leading global animal health company developing and marketing branded veterinary products to improve livestock productivity and welfare, announces that on 9 September 2026, nominal cost conditional share options were granted under the Company’s Long Term Incentive Plan (“LTIP”) over 404,526 ordinary shares in the Company (representing approximately 0.60 percent of the Company’s issued share capital) to the Executive Directors listed below.

Name	Position	Number of Share Awards
David Hallas	Chief Executive Officer	232,449
Chris Wilks	Chief Financial Officer	172,077

These awards under the LTIP are subject to performance conditions being met which have been set by the Company’s Remuneration Committee and relate to Total Shareholder Return (“TSR”) and Research and Development (“R&D”) targets. Subject to the performance conditions being met, awards will vest after the end of a three-year vesting period. Further details on the LTIP can be found in the Company’s 2026 Annual Report which was published on 5 August 2026.

In addition, on 9 September 2026, nominal cost restricted share units (“RSUs”) over 50,566 ordinary shares in the Company (representing approximately 0.07 percent of the Company’s issued share capital) were granted to the two Executive Directors listed below. The RSUs were granted under the LTIP and will vest after the end of a three-year vesting period but are not subject to performance conditions being met. Further details on the RSUs can be found in the Company’s 2026 Annual Report which was published on 5 August 2026.

Name	Position	Number of RSUs
David Hallas	Chief Executive Officer	29,056
Chris Wilks	Chief Financial Officer	21,510

-Ends-

Contacts

ECO Animal Health Group plc David Hallas (Chief Executive Officer) Christopher Wilks (Chief Financial Officer)	020 8447 8899
ICR Healthcare (Financial PR) Mary-Jane Elliott Jessica Hodgson Phillip Marriage	020 3709 5700

Singer Capital Markets (Nominated Adviser & Joint Broker) Jen Boorer Sara Hale James Fischer	020 7496 3000
Panmure Liberum (Joint Broker) Emma Earl Will Goode Mark Rogers Rupert Dearden	020 3100 2000
Equity Development Hannah Crowe Matt Evans	020 7065 2692

About ECO Animal Health

ECO Animal Health (AIM: EAH) is a leading global animal health company, developing and marketing branded veterinary products that optimise livestock wellbeing and productivity.

The Group’s proprietary lead product, Aivlosin® is a market leading antibiotic for the treatment of respiratory and intestinal diseases in pigs and poultry, distributed to over 70 markets through an established commercial platform.

ECO Animal Health is also investing in the next generation of animal health products through a self-funded R&D pipeline, with a particular focus on prevention and vaccines. The first product from ECO’s pipeline, ECOVAXXIN® MS, a poultry vaccine targeting Mycoplasma synoviae infection, was commercially launched in the EU in July 2026.

Headquartered in the UK, with a global presence, ECO Animal Health employs over 200 people worldwide.

View the Group’s website or LinkedIn page for further information.

PDMR Notification - ECO LTIP Nominal Cost Conditional Share Awards

1.	Details of the person discharging managerial responsibilities / person closely associated
a.	Name	David Hallas
2.	Reason for the notification
a.	Position/status	Chief Executive Officer
b.	Initial notification /Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Eco Animal Health Group Plc
b.	LEI	2138009XN9DJ3YP7OB55
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the Financial instrument, type of instrument Identification code	Options over ordinary shares of 5p each. GB0032036807
b.	Nature of the transaction	Award of nominal cost conditional share awards under the Company’s LTIP (“LTIP”) Award of nominal cost restricted share units (“RSUs”)
c.	Price(s) and volume(s)	Price(s) Volume(s) 1. LTIP 5p 232,449 2. RSUs 5p 29,056
d.	Aggregated information Aggregated volume Price	n/a
e.	Date of the transaction	9 September 2026
f.	Place of the transaction	Off Market

1.	Details of the person discharging managerial responsibilities / person closely associated
a.	Name	Chris Wilks
2.	Reason for the notification
a.	Position/status	Chief Financial Officer
b.	Initial notification /Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Eco Animal Health Group Plc
b.	LEI	2138009XN9DJ3YP7OB55
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the Financial instrument, type of instrument Identification code	Options over ordinary shares of 5p each. GB0032036807
b.	Nature of the transaction	Award of nominal cost conditional share awards under the Company’s LTIP (“LTIP”) Award of nominal cost restricted share units (“RSUs”)
c.	Price(s) and volume(s)	Price(s) Volume(s) 1. LTIP 5p 172,077 2. RSUs 5p 21,510
d.	Aggregated information Aggregated volume Price	n/a
e.	Date of the transaction	9 September 2026
f.	Place of the transaction	Off Market

 

END